Aortic valve disease (AVD) is a growing public health problem, and the pathogenesis underlying AVD is complex. The lack of durable bioprostheses and pharmacologic therapies remain central needs in care. The purpose of this review is to highlight recent clinical studies that impact the care of children with AVD and is to explore ongoing translational research efforts.
INTRODUCTION
Aortic valve disease (AVD) is a progressive disease process that results in greater than 25 000 deaths annually in the United States [1] . Aortic valve malformation, typically bicuspid aortic valve (BAV), is an independent risk factor for the development of AVD and is present in the majority of cases at any age, suggesting a developmental cause [2, 3] . Increasing evidence suggests that AVD is not simply a degenerative process, and genetic and developmental abnormalities are involved in disease initiation and progression before established environmental factors contribute to pathogenesis [4, 5] . The management of pediatric AVD is different from adult AVD for two basic reasons: the small size of the patient creates surgical considerations and the absence of comorbid cardiovascular diseases that are common in the adult patient with AVD.
Recently, the American Heart Association (AHA) and American College of Cardiology (ACC) revised the guidelines for the management of patients with heart-valve disease [6] , and a working group from the National Heart and Lung and Blood Institute made recommendations outlining research priorities moving forward [7] , including identification of genetic and clinical risk factors for early AVD, development of animal models that duplicate the natural history of AVD, and identification of pharmacologic-based therapies for early intervention. Currently, two fundamental gaps in the standard of clinical care for AVD are the need for drugs that directly treat early disease processes and the need for durable bioprosthetic valves.
The genetic basis of BAV is well established, but only a small number of genes have been associated with AVD. Mutations in NOTCH1 and SMAD6 only account for approximately 2 to 3% of cases [8] [9] [10] . Family-based studies have determined that the inheritance of BAV is complex and polygenic [11] . Interestingly, family-based studies have also suggested that although BAV is determined largely by genetic effects, the phenotypic variability of AVD is determined, in part, by nongenetic factors [12] , underscoring the importance of distinguishing between early and late disease processes. The clinical utility of genetic testing in the context of cardiovascular malformation and disease has been carefully defined [13] , and the advent of clinical and research exome testing promises to accelerate the discovery of causal and modifying variants, as well as clinically meaningful phenotype stratification [14, 15] .
The Pharmacogenomic Resource for Enhanced Decisions in Care and Treatment project is an early example of the operational implementation of personalized medicine, whereby genotype information (e.g., CYP2C19 variants associated with reduced clopidogrel metabolism) was integrated into the electronic medical record and was shown to impact clinical decision making (which drug to prescribe) in an individual specific manner [16] . The Family Healthware Impact Trial has demonstrated the power of family history and patient empowerment by using a web-based tool to assess familial risk and provide a personalized prevention plan [17] , which may be a practical and complementary tool.
As the United States Food and Drug Administration now includes pharmacogenomics data in drug labels, and clinical trials increasingly require genotype and biomarker information [18] , companion diagnostics, or the use of specific diagnostic tests such as genotype and biomarker panels that can be used to identify a subset of patients that will benefit from a specific therapy or should not receive it [19] , has gained favor, especially in oncology [20] [21] [22] , as an effective way to improve patient care and advance the use of personalized medicine.
Herein, we review recent advances in the care of patients with AVD, especially children, as well as ongoing translational efforts that appear poised to impact clinical practice paradigms in the near future.
BIOPROSTHETIC VALVES ARE INCREASINGLY USED IN YOUNG PATIENTS, BUT CONTINUE TO LACK DURABILITY
Aortic valve replacement procedures using mechanical prosthetic valves have demonstrated excellent long-term durability, but are associated with a number of significant complications, including thromboembolism and bleeding related to the need for anticoagulation ( Table 1 ). Aortic valve replacement in children is complicated further by the fact that children are growing, such that over time the child 'outgrows' the prosthetic valve and requires replacement, often with multiple surgeries. The increasing use of bioprosthetic valves in pediatric and young adult patients recognizes the emphasis patients place on avoiding the complications of anticoagulation, as well as activity restrictions or lifestyle modifications [23, 24] . There is substantial interest in developing bioprosthetic valves that grow with the patient and do not require reintervention. Several recent studies have advanced our understanding of the durability of commonly used bioprosthetic valves.
Une et al. ] reported the 20-year durability of the aortic Hancock II bioprosthesis in young patients. Although good long-term results have been demonstrated in older patients, there is limited information on durability beyond the first decade in young patients. Because younger age is a strong predictor of structural valve deterioration, the research group examined outcomes in 'young patients' specifically. Over 300 patients aged 17-59 years were studied, and a significant increase in valve failure was demonstrated in the second decade after implantation. Specifically, freedom from major adverse valve-related events decreased from 74% at 10 years to 17% at 20 years. Likewise,
KEY POINTS
Aortic valve replacement using bioprosthetics is effective but improvements in durability are needed.
New circulating and imaging markers are being developed that predict AVD severity risk, which may be useful for the management of early AVD.
Preclinical large animal studies are testing new bioprostheses that may be more durable because of constructive remodeling that allows the bioprosthetic to recruit resident cells and transform the bioprosthetic construct into a native valve.
Preclinical studies in mouse models are elucidating the natural history and pathogenesis of AVD, and targeting developmental programs for new therapies.
Companion diagnostics may be feasible to advance personalized medicine for patients with early AVD as the underlying genetic causes are defined and predictive biomarkers are identified.
the freedom from reoperation decreased from 84 to 25%, and in the less-than-40 age subgroup this decreased further to 14%. Indeed, the strongest predictor of the need for reoperation was age (P < 0.01), but prosthesis-patient mismatch also predicted the need for reoperation (P ¼ 0.045), suggesting that surgical technique impacted a subset of cases, but also highlighting the possibility that smaller prostheses in younger patients are exposed to increased mechanical stresses that contribute to faster degeneration. Importantly, this cohort did not include pediatric patients and therefore does not address the potential issue of lack of valve growth.
Saleeb et al. ] report their experience in a small series of pediatric patients using two types of bovine pericardial bioprostheses; the Mitroflow LXA and the Magna or Magna Ease valves. Freedom from valve failure at 3 years among those patients with a Mitroflow LXA valve was only 18% and progression to severe stenosis occurred over a median of only 6 months. Importantly, these patients were younger and smaller and received smaller valves (all known risk factors for valve failure) when compared with the Magna or Magna Ease group, but 40% of the Mitroflow LXA valve failures occurred in fully grown young adults, suggesting that these factors do not fully explain the failures. Of note, many of these patients had additional cardiovascular malformations, genetic syndromes and a history of infective endocarditis, confounding generalizability. Interestingly, failure in all cases was due to intrinsic calcification without inflammation that resulted in decreased effective orifice area and stenosis. The authors concluded that patients who have received a Mitroflow LXA pericardial aortic bioprosthetic valve are at increased risk of rapid valve failure and recommended that those patients who have been implanted already undergo increased echocardiographic surveillance, as rapid disease progression was not coincident with symptomatology. Taken together, the findings from these two studies identify a continued need to improve the durability of bioprosthetic alternatives for pediatric patients.
ADVANCES IN CATHETER-BASED INTERVENTIONS PROMISE INCREASING USE OF LESS INVASIVE VALVE REPLACEMENT PROCEDURES IN THE FUTURE
Catheter-based balloon valvuloplasty remains an effective way to treat aortic stenosis in children and postpone, if not prevent, the need for valve replacement; however, newer catheter-based procedures are delivering replacement valves and these procedures may be applicable to children. Transcatheter aortic valve replacement (TAVR) is increasingly becoming the preferred approach to intervention in a number of AVD patient subsets, including high-risk patients and those with prosthetics already in place using a valve-in-valve approach [27] . Most recently, Adams et al.
[28] reported early findings using TAVR with a selfexpanding prosthesis and demonstrated increased survival and decreased major cardiovascular and cerebrovascular events. The Melody valve (Medtronic, Minneapolis, Minnesota, USA), a bovine jugular vein sewn into a stent, has been used successfully for pulmonary valve replacement using a Humanitarian Device Exemption; the effectiveness of the device has not yet been demonstrated. In the context of lower right-sided heart pressures, anecdotal evidence has been positive, but attempts to use the Melody valve on the left-sided aortic valve have not been reported. Interestingly, the first report of various forms of complex cardiovascular malformation using surgical or hybrid approaches [30] . Taken together, these observations suggest that the Melody valve may be a therapeutic option in pediatric patients with complex cardiovascular malformation to avoid additional surgery and potentially delay the need for heart transplantation, and should be tested in children and adults with isolated AVD. AVD is often associated with aortopathy and this presents unique surgical challenges. Often the degree of AVD at the time of aortic root replacement does not indicate replacement and the surgeon must decide between an aortic valve-sparing procedure or replacement of both the aortic root and aortic valve. [32] recently reported their experience with valve sparing operations in 371 nonsyndromic patients and concluded that both reimplantation and remodeling approaches to valve-sparing aortic root replacement result in excellent clinical outcomes, including 95% freedom from reoperation at 18 years despite a slow, but progressive, deterioration of valve function. Importantly, the new AHA or ACC Guidelines for valve disease recognize the BAV-aortopathy association and have initiated specific recommendations for this subgroup [6] .
NEW THERAPIES TO TREAT EARLY AORTIC VALVE DISEASE AND BIOMARKERS THAT IDENTIFY THOSE AT RISK ARE NEEDED
There are currently no pharmacologic therapies to directly treat underlying AVD processes, only symptoms of heart failure in the context of advanced disease. A recent study examining the larger simvastatin and ezetimibe in aortic stenosis study examined the use of statins in the context of asymptomatic patients with mild aortic stenosis and no comorbidities [33 && ]. The authors concluded that treatment with statins is not associated with a significant reduction in cardiovascular death, need for aortic valve replacement, heart failure due to progression of AVD, or cardiovascular ischemic events at mild or moderate degrees of AVD, consistent with the primary outcome from the seminal study [34] . This interesting finding has been supported recently by a large-scale human genetics study that examined 1435 single nucleotide polymorphisms in 11 genes associated with cholesterol metabolism from 382 patients with AVD and found that these variants do not influence disease susceptibility and functional characteristics of cholesterol metabolism are not altered as they are in the context of coronary artery disease [35] . Taken together, these findings suggest that atherosclerosis-related processes contribute to disease progression but other factors underlie the cause of AVD and contribute to disease initiation.
Other large clinical studies have begun to explore the possibility of using circulation and imaging biomarkers. Linefsky et al. [36] examined the nearly 7000 participants of the Multi-Ethnic Study of Atherosclerosis and showed that serum phosphate levels are associated with aortic valve calcification, but a number of phosphate metabolism pathway markers are not, identifying a potentially modifiable risk factor and a number of important future studies. Dusenbery et al. [37 & ] analyzed young patients with congenital aortic stenosis by cardiac magnetic resonance measuring myocardial extracellular volume fraction. The authors found that the volume fraction is significantly elevated and associated with a greater number of aortic valve interventions and diastolic dysfunction, but not severity of stenosis, left ventricular mass or indexes of systolic dysfunction. Although most of the patients studied had a normal extracellular volume fraction, this measure potentially represents a new noninvasive marker that may be clinically useful for risk stratification and monitoring the response to various therapies.
ONGOING EFFORTS IN TRANSLATIONAL RESEARCH IDENTIFY NEXT STEPS
In an ovine model, a novel bioprosthetic tricuspid valve (CorMatrix Cardiovascular, Inc., Roswell, Georgia, USA) constructed from noncross-linked extracellular matrix derived from porcine small intestinal submucosa has been shown to adopt the appearance of a native valve by 4 months with normal valve function at 1 year [38 && ]. Importantly, histopathology was characterized by cell recruitment and constructive tissue remodeling with no evidence of inflammation. In a small series of patients requiring aortic valve repair, CorMatrix material was used with limited evidence of resorption and no evidence of tissue remodeling at less than 9 months [39] . One explanation for why the constructive remodeling was not reproduced may be that only a small area of patch material was implanted, not a valve scaffold, limiting cell recruitment and therefore tissue remodeling.
Tissue-engineered heart valves (TEHV) continue to be an area of active investigation because of their promise to be a permanent valve replacement. TEHV refers to the development of a completely biological heart valve in vitro by isolating the patient's own cells, including bone marrow, adipose and induced pluripotent stem cells, creating a scaffold and implanting this 'living valve' construct back into the patient, providing the benefits of ongoing physiologic remodeling and growth. Despite the sensational failure of an early TEHV in children [40] , there has been substantial interest in refining this approach. As the primary cause of failure of TEHV in vivo has been attributed to contraction of the cusps due to the hyper-contractile properties of the transplanted cells, which results in cusp shortening and ultimately valve regurgitation, Syedain et al. [41 & ] examined the tensile properties of a scaffold developed from human neonatal dermal fibroblast cells and showed that both cell removal and compete recellularization was feasible without altering the matrix organization or structure. Additional studies have shown that TEHVs that fabricate native valve extracellular matrix organization (trilaminar structure) ex vivo promoted the deposition of valve interstitial cells [42] , anisotropic scaffolds (in which the fibers are unidirectionally oriented) resulted in matrix production of collagens and elastins and increased recovery of the physiologic valve interstitial cell phenotype [43] , and the use of a specific hydrogel platform maintains quiescent valve interstitial cell phenotype [44] . Taken together, these advances suggest that significant progress is being made that improves the stability of scaffolds and prevents the cells from damaging it, and therefore a viable TEHV may be developed in the near future.
Mutant mouse models have begun to focus on defining natural history as a way to identify early disease processes and test potential new therapies. The eNOS-/-and Notch þ/mice both show aortic valve tissue architectural changes and mild mineralization with small subsets of mutants demonstrating BAV without AVD [45, 46] . Bosse et al. [47 && ] created a double mutant that demonstrates a nearly completely penetrant BAV phenotype with AVD and shows that loss of endothelial nitric oxide regulates Notch signaling in aortic valves, which inturn accelerates calcification. Weiss et al. [48] performed a preclinical study in Ldlr-/-; Apob100/100 mice, a model of latent calcific AVD, to test the efficacy of osteoprotegerin, a RANK signaling inhibitor that promotes demineralization. They demonstrated attenuated calcification and inflammation but not fibrosis or AVD, suggesting that osteoprotegerin protects predisposed aortic valve tissue from developing calcific AVD and may be a useful therapy early in disease course. Taken together, these studies elucidate AVD pathogenesis and identify new therapeutic targets.
Our understanding of cell-matrix architecture in aortic valve tissue is critical to both identify new therapeutic targets. Wang et al. [49 && ] carefully examined progenitor cell markers from porcine semilunar valves and identified subsets of resident valve interstitial cells that are more prone to calcification (ABCG2þ) and may be the valve's resident myofibroblasts (OB-CDHþ). Myofibroblasts have been difficult to phenotype in valve tissue, but are generally thought to be critical for both repair and disease processes, and most importantly may provide key insights into mechanisms underlying disease progression. Recent efforts have demonstrated the importance of understanding dynamic patterns of protein expression in the context of healthy aortic valve tissue homeostasis. For example, Dupuis et al. [50] recently described comprehensive and elegant expression patterns for small leucine-rich proteoglycans, small molecules with specialized roles in the cardiovascular extracellular matrix. Balaoing et al. [51] identified differences in specific valve maintenance proteins secreted by valve endothelial cells with age, identifying some changes that may translate to age-associated risk and demonstrating the complex regulation of homeostasis. Combining these types of studies with emerging proteomics initiatives [52] will allow a more comprehensive approach to understanding valve tissue homeostasis and developing therapeutics using protein engineering [53] .
CONCLUSION
Outcomes for patients with AVD continue to improve, and the research community has a welldefined agenda for further progress. Translational research efforts appear to be on the verge of many important applications. Mutidisciplinary teams are required to combine the disparate expertise of cardiology, cardiothoracic surgery, human genetics, developmental biology, biomedical engineering, and bioinformatics, among others. Valve Centers of Excellence that incorporate pediatric programs will create unique bridges that will enhance clinical and research efforts alike. Because pharma is becoming more selective about drug discovery efforts [54, 55] there appears to be an increased interest in 'disease management,' including companion diagnostics [56] [57] [58] , providing new reasons for focusing on innovation in partnership with pharma.
As gene discovery accelerates and clinical genetic testing expands, the use of genetic information for the management of patients with cardiovascular disease, including AVD, will become standard of care [14] . Companion diagnostics for specific cardiovascular diseases will advance our ability to realize the promise of personalized medicine [59] . To this end, the pediatric cardiology research community is in an excellent position to leverage consortia that combine genomics with patient care [60] . The Pediatric Cardiac Genomics Consortium is linked to the Pediatric Heart Network and, therefore, is in a position to apply combined genetic information and predictive biomarkers to new clinical trials. For example, companion diagnostics may provide a strategy to stratify the Kawasaki or Single Ventricle cohorts in clinically meaningful ways. Ultimately, more assertive care of early disease processes using genetic and clinical information will significantly improve patient care. This study reports the early outcomes of valve sparing and valve replacing aortic root replacement strategies emphasizing the need to recognize the AVD-aortopathy association.
